바이오인

In July 2012, the US Food and Drug Administration (FDA) granted marketing approval for an ingestible sensor that, when incorporated into a pill, allows users to track data on drug adherence and other key health indicators over time. Fittingly, this first-in-class technology was approved under new FDA provisions for low-risk devices that have no predicate on the market — the culmination of a four-year collaboration between regulators and the company behind the new technology, California-based Proteus Digital Health.